NCT01546532 - Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF) | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Chronic Heart Failure (CHF)

Interventions

DRUG

RLX030

RLX030 as intravenous infusion for 24 hours.

DRUG

Placebo

Intravenous infusion of Placebo over 24 hours

Trial Locations (15)

10117

Novartis Investigative Site, Berlin

20246

Novartis Investigative Site, Hamburg

37075

Novartis Investigative Site, Göttingen

91054

Novartis Investigative Site, Erlangen

Unknown

Novartis Investigative Site, Baltimore

7416 SE

Novartis Investigative Site, Deventer

9713 GZ

Novartis Investigative Site, Groningen

8601 ZR

Novartis Investigative Site, Sneek

05-825

Novartis Investigative Site, Grodzisk Mazowiecki

40-637

Novartis Investigative Site, Katowice

31-202

Novartis Investigative Site, Krakow

31-501

Novartis Investigative Site, Krakow

20-954

Novartis Investigative Site, Lublin

04-628

Novartis Investigative Site, Warsaw

58-309

Novartis Investigative Site, Wałbrzych